Male breast cancer

Current Treatment Options in Oncology

Volumn 4, Issue 2, 2003, Pages 159-164

  Volm, Matthew D ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Anastrozole; Aromatase Inhibitor; Breast Cancer; Sentinel Node; Tamoxifen

Indexed keywords

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; HUMAN; MALE; METASTASIS; PATHOLOGY; REVIEW;

BREAST NEOPLASMS, MALE; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; NEOPLASM METASTASIS;

EID: 0038504946     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-003-0017-8     Document Type: Article

References (30)

1. Rayson D, Erlichman C, Suman VJ, et al.: Molecular markers in male breast carcinoma. Cancer 1998, 83:1947–1955. DOI: 10.1002/(SICI)1097-0142(19981101)83:9<1947::AID-CNCR10>3.0.CO;2-J
2. Ribeiro G: Tamoxifen in the treatment of male breast carcinoma. Clin Radiol 1983, 34:625–628. DOI: 10.1016/S0009-9260(83)80408-5
3. Kantarjian H, Hortobagyi G, Buzdar A, Blumenschein G: Hormonal therapy for metastatic male breast cancer. Arch Intern Med 1983, 143:237–240. DOI: 10.1001/archinte.143.2.237
4. Jaiyesimi IA, Buzdar AU, Sahin A, Ross MA: Carcinoma of the male breast. Ann Intern Med 1992, 117:771–777.
5. Handesman D: Androgen actions and pharmacologic uses. In Endocrinology. Edited by DeGroot IJ. Philadelphia: WB Saunders; 2001:2232–2242.
6. Harris AL, Dowsett M, Stuart-Harris R, Smith IE: Role of aminoglutethimide in male breast cancer. Br J Cancer 1986, 54:657–660.
7. Giordano SH, Valero V, Buzdar A, Hortobagyi G: Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002, 25:235–237. Anastrozole and other third-generation aromatase inhibitors are important drugs for women who are postmenopausal with hormone receptor-positive breast cancer. The article reports on a small cohort of male patients treated with anastrozole and provides a useful discussion that suggests why aromatase inhibitors may not be as effective in men. DOI: 10.1097/00000421-200206000-00006
8. Doberauer C, Niederle N, Schmidt C: Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer 1988, 62:474–478. DOI: 10.1002/1097-0142(19880801)62:3<474::AID-CNCR2820620305>3.0.CO;2-2
9. Vorobiof DA, Falkson G: Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer. Cancer 1987, 59:688–689. DOI: 10.1002/1097-0142(19870215)59:4<688::AID-CNCR2820590404>3.0.CO;2-E
10. Cutuli B, Lacroze M, Dilhuydy JM, et al.: Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995, 31:1960–1964. DOI: 10.1016/0959-8049(95)00366-5
11. Willsher PC, Leach IH, Ellis IO, et al.: A comparison outcome of male breast cancer with female breast cancer. Am J Surg 1997, 173:185–188. DOI: 10.1016/S0002-9610(97)89592-X
12. Borgen PI, Senie RT, McKinnon WM, Rosen PP: Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol 1997, 4:385–388. DOI: 10.1007/BF02305550
13. Ribeiro G, Swindell R: Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992, 65:252–254.
14. Anelli TF, Anelli A, Tran KN, et al.: Tamoxifen administration is associated with a high rate of treatmentlimiting symptoms in male breast cancer patients. Cancer 1994, 74:74–77. The article provides important information about the side-effect profile of tamoxifen in men. DOI: 10.1002/1097-0142(19940701)74:1<74::AID-CNCR2820740113>3.0.CO;2-#
15. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
16. Bagley CS, Wesley MN, Young RC, Lippman ME: Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 1987, 10:55–60. DOI: 10.1097/00000421-198702000-00013
17. Patel HZ, Buzdar AU, Hortobagyi GN: Role of adjuvant chemotherapy in male breast cancer. Cancer 1989, 64:1583–1585. DOI: 10.1002/1097-0142(19891015)64:8<1583::AID-CNCR2820640804>3.0.CO;2-Q
18. Margaria E, Chiusa L, Ferrari L, et al.: Therapy and survival in male breast carcinoma: a retrospective analysis of 50 cases. Oncol Rep 2000, 7:1035–1039.
19. Overgaard M, Hansen PS, Overgaard J, et al.: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b trial. N Engl J Med 1997, 337:949–955. DOI: 10.1056/NEJM199710023371401
20. Ragaz J, Jackson SM, Le N, et al.: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997, 337:956–962. DOI: 10.1056/NEJM199710023371402
21. Schuchardt U, Seegenschmiedt MH, Kirschner MJ, et al.: Adjuvant radiotherapy for breast carcinoma in men: a 20-year clinical experience. Am J Clin Oncol 1996, 19:330–336. DOI: 10.1097/00000421-199608000-00002
22. Stranzl H, Mayer R, Quehenberger F, et al.: Adjuvant radiotherapy in male breast cancer. Radiother Oncol 1999, 53:29–35. DOI: 10.1016/S0167-8140(99)00122-X
23. Farrell J, Adair F: Effect of orchiectomy on skeletal metastases from cancer of the male breast. Science 1941, 95:654–657.
24. Hill AD, Borgen PI, Cody HS: Sentinel node biopsy in male breast cancer. Eur J Surg Oncol 1999, 25:442–443. DOI: 10.1053/ejso.1999.0674
25. Howell A, Robertson JF, Quaresma Albano J, et al.: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002, 20:3396–3403. DOI: 10.1200/JCO.2002.10.057
26. Andre S, Fonseca I, Pinto AE: Male breast cancer: a reappraisal of clinical and biologic indicators of prognosis. Acta Oncol 2001, 40:472–478. DOI: 10.1080/028418601750288190
27. Dawson PJ, Paine TM, Wolman SR: Immunocytochemical characterization of male breast cancer. Mod Pathol 1992, 5:621–625.
28. Bruce DM, Heys S, Payne S, et al.: Male breast cancer: clinico-pathological features, immunocytochemical characteristics, and prognosis. Eur J Surg Oncol 1996, 22:42–46. DOI: 10.1016/S0748-7983(96)91418-3
29. Joshi MG, Lee A, Loda M, et al.: Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996, 77:490–498. DOI: 10.1002/(SICI)1097-0142(19960201)77:3<490::AID-CNCR10>3.0.CO;2-#
30. Pich A, Margaria E, Chiusa L: Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. J Clin Oncol 2000, 18:2948–2956.